SEOM Clinical guidelines for the treatment of metastatic prostate cancer

Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptom...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2014-12, Vol.16 (12), p.1060-1066
Main Authors: Cassinello, J., Climent, M. A., González del Alba, A., Mellado, B., Virizuela, J. A.
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Antineoplastic Agents - therapeutic use
Clinical Guides in Oncology
Humans
Male
Medicine
Medicine & Public Health
Oncology
Prostatic Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged: pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently required.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-014-1225-3